Good Laboratory Practice (GLP)
Advancing to GLP toxicology studies
Experimentica is a recognized ophthalmic CRO known for its preclinical ocular models built on validated in vitro and in vivo platforms. For more than a decade our work has supported the development of hundreds of novel therapies across a wide range of mechanisms and delivery approaches, using advanced in life monitoring technologies and strong scientific expertise. Building on this foundation, we are now expanding our capabilities to include GLP toxicology studies to help our clients progress toward regulatory submissions for their preclinical assets and to fill in the gaps for their clinical drug candidates.
GLP ocular toxicology studies
Experimentica’s upcoming preclinical GLP safety and toxicology studies are designed for clients developing innovative ophthalmic drugs and delivery approaches. The GLP test facility will be equipped with advanced ocular imaging and visual function assessment technologies that enable detailed characterization of ocular adverse events.
Our GLP services will include a comprehensive range of study types:
Acute, subacute, subchronic, and chronic exposure assessments
Intraocular drugs and implants, topical, and systemic
Small molecules, biologics, cell therapy, gene therapy, and other nucleic acid-based therapies
Mouse, rat, and rabbit
Ocular tolerability, structural integrity, and functional outcomes
These GLP services are designed to align with Experimentica’s existing non-GLP ocular models, supporting a smooth transition for our clients from non-GLP efficacy to GLP-compliant safety and toxicology studies, providing a coherent pathway toward regulatory submissions.
Experimentica – Your future GLP toxicology CRO
As we finalize our GLP-ready study portfolio, we welcome early discussions with teams preparing for IND-enabling programs or requiring additional data to support clinical-phase ophthalmic drug candidates. If you are planning your next safety or toxicology assessment or exploring study designs for your ophthalmic asset, our team is available to discuss study options, timelines, and integrated development pathways.
The establishment of the GLP-compliant test facility in Kuopio, Finland is co-funded by the European Union.
